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CHAPTER I 
 
 
INTRODUCTION 
Background 
 Lameness is an important problem in cattle operations due to its effects on animal 
health and production as well as animal welfare.1  The etiology of lameness is often 
multifactorial.  Regardless of the cause, chronic lameness frequently leads to decreased 
reproductive performance,2-5 decreased milk production6,7 and premature culling.8-10  The 
incidence and prevalence of lameness in dairy cattle have received considerable 
investigation.11-16  A recent study reported a lameness prevalence of 24.6% in Minnesota 
dairy cows.17  In one study in dairy cows in England, lameness accounted for 27% of the 
health costs.18  Similar studies in beef cattle are limited; however, the 1999 National 
Market Cow and Bull Beef Quality Audit found an increased incidence of lameness in 
culled beef cows and bulls compared to the 1994 National Non-Fed Beef Quality Audit.19  
The causes of lameness in cattle have been recently reviewed.20,21   A systematic 
compilation of the literature on lameness has also been published.22 
 Infectious processes such as osteomyelitis, septic arthritis, and tenosynovitis, 
collectively known as deep digital sepsis (DDS), are among the most debilitating causes 
of lameness, often resulting in significant loss of function or destruction of the animal.23  
These conditions often occur secondary to more common causes of lameness such as sole 
ulcers and interdigital necrobacillosis20,24,25 and may or may not be associated with 
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significant cellulitis of local soft tissues.   Antimicrobial therapy alone is generally 
ineffective for DDS and must be accompanied by surgical therapy including debridement, 
drainage and lavage, and stabilization of affected tissues.23, 26-31  In addition, systemic  
antibiotics may need to be administered for a long period of time to eliminate infection.  
A treatment period of four to six weeks is generally recommended.23,32-35  Penetration of 
antibiotics into bone does not appear to be a limiting factor as numerous antibiotics reach 
therapeutic levels in normal bones and joints after systemic administration.36  Reasons for 
the limited success of antibiotic therapy alone include the presence of necrotic material, 
poor vascular perfusion, the presence of inflammatory mediators, entrapping of bacteria 
in fibrin, and the presence of biofilm or glycocalyx surrounding foreign material or 
surgical implants.28,37-41  Treatment options for orthopedic infections in cattle23,31,42 and 
horses28,30 have been reviewed. 
 Regional intravenous antibiotic perfusion (RIVP) of the distal limb may offer 
several advantages over systemic antibiotic administration when treating cases of DDS.  
The advantages include higher concentrations of antibiotic at the site of infection and 
reduced potential for systemic toxicity due to lower systemic drug concentrations.40,43,44  
Other potential advantages include decreased duration of antibiotic therapy and reduced 
drug costs. 
 Florfenicol is a phenolic antibiotic that inhibits the 50S subunit of the bacterial 
ribosome.45  Florfenicol is approved for use in the treatment of bovine respiratory disease 
complex and foot rot in cattlea.  Although labeled for intramuscular or subcutaneous 
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administration, florfenicol can be safely administered intravenously.46-50  These factors 
make florfenicol a logical choice for evaluation in the application of regional antibiotic 
perfusion.   
 Objective 
 The objective of this study was to define the pharmacokinetics of florfenicol in 
digital blood, metatarsophalangeal synovial fluid, and jugular blood samples following 
regional intravenous administration of 2.2 mg/kg florfenicol to the distal limb of cattle.  If 
adequate concentrations can be achieved and maintained, administration of florfenicol in 
this manner may be a useful tool in the treatment of infectious conditions involving the 
deep structures of the foot of cattle. 
Florfenicol Pharmacology 
 Florfenicol is a prescription antibiotic labeled for use in the United States for the 
treatment of cattle, pigs, catfish, and salmon.  It is a derivative of thiamphenicol, in which 
the hydroxyl group has been replaced by fluorine (Figure 1).  Like thiamphenicol, 
florfenicol lacks the p-nitro group which is thought to cause the dose-independent, 
irreversible bone marrow suppression associated with chloramphenicol.  Substitution of 
the 3-hydroxyl group with fluorine results in a molecule that is not susceptible to 
chloramphenicol transacetylases.51  In cattle, florfenicol is approved for the treatment of 
bovine respiratory disease caused by Mannhaemia haemolytica, Pasteurella multocida, 
and Histophilus somnus and for the treatment of infectious pododermatitis caused by 
Bacteroides melaninogenicus and Fusobacterium necrophorum.  Florfenicol is labeled 
for intramuscular administration at 20 mg/kg repeated in 48 hours or subcutaneous 
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administration once at 40 mg/kg (NADA 141-063b).  In Canada, florfenicol is also 
approved for the treatment of infectious keratoconjunctivitis caused by Moraxella bovis. 
 Florfenicol has a broader spectrum of activity than chloramphenicol and 
thiamphenicol and is typically considered bacteriostatic.  Similar to chloramphenicol, 
florfenicol has high bioavailability and wide tissue distribution.  In cattle, florfenicol is 
excreted primarily by the kidney as unchanged drug.50 
 
Figure 1.  Chemical structure of florfenicol.  Image obtained from 
www.umesc.usgs.gov/aquatic/drug_research/florfenicol/florfenicol_structure_400.gif 
 
 
 
 
 
 
 
 
                                                 
b http://www.fda.gov/cvm/FOI/141-063s011499.pdf 
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Extralabel Drug Use in Food Animals 
 Using antibiotics in regional perfusion systems constitutes extra-label drug use.  
The Animal Medicinal Drug Use Clarification Act of 1996 (AMDUCA) allows for the 
use of Food and Drug Administration (FDA) approved drugs in an extra-label manner as 
long as certain conditions are met.  The reader is referred to FDA’s AMDUCA websitec 
for more information.  In the veterinary literature, aminoglycosides are the most common 
antibiotics used in regional perfusion for the treatment of orthopedic infection in species 
other than cattle.  Although not prohibited by AMDUCA, the use of aminoglycosides in 
food animals is discouraged due to the need for extended withdrawal periods.52  Also, 
several antibiotics that have reportedly been used in local delivery systems are prohibited 
for use in food animals.  The reader is referred to the Food Animal Residue Avoidance 
Databank (FARAD)d for a current list of drugs prohibited for extra-label use in food 
animals.  Due to the limited availability of antibiotics suitable for regional perfusion in 
food animals, the potential use of florfenicol in regional perfusion warrants investigation. 
Extra-label use of florfenicol is not prohibited as long as the provisions of AMDUCA are 
followed.  The FDA has established a tolerance level of 3.7 parts per million for the 
florfenicol metabolite, florfenicol amine, in cattle liver.  No tolerance level has been 
established in milk so any detectable residue is considered a violation.e   
 
 
 
 
                                                 
c www.fda.gov/cvm/amducatoc.htm 
d www.farad.org/ 
e http://www.cfsan.fda.gov/~acrobat/mi-06-5.pdf 
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CHAPTER II 
 
 
REVIEW OF LITERATURE 
 
Pharmacokinetics of Florfenicol 
 The pharmacokinetics of florfenicol have received considerable investigation in a 
variety of animal species.  The broad application of this antimicrobial is an indication of 
its utility in veterinary medicine.   The pharmacokinetics of florfenicol have been 
described in swine,53-56 camels,57 goats,57-59 sheep,57,60,61 elk,62 chickens,63-65 muscovy 
ducks,66 rabbits,67,68 loggerhead sea turtles,69 rhesus macaques,70 horses,71 atlantic 
salmon,72,73 catfish,74 cod,75 koi carp,76 red pacu,77 white spotted bamboo sharks,78 and 
cattle.47-50,79-84 
 Selected pharmacokinetic parameters from several studies investigating the 
florfenicol pharmacokinetics in pigs are presented in Table 1.  Jiang et al.53 studied the 
pharmacokinetics of florfenicol in pigs following intravenous (IV), intramuscular (IM), 
and oral (PO) dosing of 20 mg/kg florfenicol where as Voorspoels et al.54 reported the 
florfenicol pharmacokinetics in pigs following IM and PO doses of 15 mg/kg.  
Additionally, Jiang et al.53 examined the effect of feed intake on the pharmacokinetics of 
orally administered florfenicol.  Fasted pigs exhibited a higher peak concentrations 
(Cmax) where as fed pigs exhibited a longer mean residence time.  The Area Under the 
Curve (AUC) and elimination half life were not different between the two groups.  Liu55 
compared the pharmacokinetics of florfenicol in healthy pigs and pigs experimentally 
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infected with Actinobacillus pleuropneumoniae.  These authors found no statistical 
differences in pharmacokinetic parameters between the healthy and diseased pigs.  In two 
separate studies,53,55 the Cmax achieved after PO dosing was higher than that achieved 
after IM dosing.    In another study, Liu et al.,56 reported the tissue pharmacokinetics of 
florfenicol in pigs.  This study found the highest florfenicol concentrations in the kidney 
and lung while liver and muscle exhibited the longest elimination half lives. 
 Several investigators have evaluated the pharmacokinetics of florfenicol in small 
ruminant species.  The results of these studies are summarized in Tables 2-4.  Atef et al.58 
and Ali et al.57 describe the pharmacokinetics of florfenicol after IV and IM 
administration at 20 mg/kg to goats.  Both studies report good tissue distribution and 
bioavailability as well as a prolonged elimination half life after IM administration when 
compared to IV administration.  In another study, Atef et al.59 found significant 
differences in pharmacokinetic parameters depending on the assay method used.  These 
authors administered florfenicol at 20 mg/kg through both IV and IM routes.  The 
samples were then divided and analyzed using High Pressure Liquid Chromatography 
(HPLC) and a microbiologic assay.  For the IV study, the HPLC assay revealed 
significantly higher initial concentrations and AUC values, lower Volume of Distribution 
at steady state (Vdss) and Clearance (Cl) values, and longer elimination half lives 
compared to the microbiologic assay.  The HPLC assay also revealed significantly higher 
values for AUC and bioavailability for the IM study.  These findings indicate that care 
should be taken when comparing results obtained by different analytical methods.  
Jianzhong et al.60 described larger AUC values and longer elimination half lives for 
florfenicol administered to sheep at 20 mg/kg and 30 mg/kg by IV and IM routes when 
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compared to values reported for goats59.  Lane et al.61 reported values of 206 ± 31 
μg·h/ml, 34.7 ± 9.6 hr, and 65.0 ± 12.2 % for AUC, elimination half life, and 
bioavailability respectively, following subcutaneous (SQ) dosing of 40 mg/kg florfenicol 
once daily for three days in sheep.  The data presented from this study in Table 3 were 
obtained after the first SQ dose so that more accurate comparisons could made with other 
values in the table.  The pharmacokinetics of florfenicol in goats, sheep, and camels were 
compared by Ali et al.57  These authors state that while the data from the three species are 
similar, the rate and extent of absorption appear lower in camels compared to sheep and 
goats.  Evaluation of the pharmacokinetics of florfenicol following administration of 40 
mg/kg SQ to North American Elk revealed a shorter elimination half life compared to 
cattle, leading the authors to recommend once daily dosing of florfenicol in this species.62   
 The pharmacokinetics of florfenicol in broiler chickens and Muscovy ducks have 
been defined.  A summary of the pharmacokinetic parameters reported in these studies is 
reported in Tables 5 and 6, respectively.  Afifi et al.63 defined the pharmacokinetics of 
florfenicol in chickens following IV, IM, and PO doses of 30 mg/kg.  These authors also 
reported tissue concentrations of florfenicol following multiple IM and PO doses of 30 
mg/kg.  They found that the kidney and bile had the highest concentrations and that 
florfenicol could not be detected in any tissue except bile after 72 hours.  Florfenicol 
could not be detected in bile after 96 hours.  Shen et al.65 described the pharmacokinetics 
of florfenicol in chickens following IV, IM and PO doses of 15 mg/kg and 30 mg/kg.  
These authors found that florfenicol exhibited very high bioavailability following both 
IM and PO dosing but that it was rapidly eliminated, leading the authors to recommend 
twice daily dosing to maintain adequate concentrations.  Infection with Escherichia coli 
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had little effect on the pharmacokinetics of florfenicol in broiler chickens.64  Pasteurella 
multocida infection in Muscovy ducks resulted in lower serum florfenicol concentrations 
and shorter elimination half lives.66  In this study, both healthy and diseased birds 
exhibited greatly increased elimination half lives compared to values reported for 
chickens. 
 Two reports describe the pharmacokinetics of florfenicol in rabbits.67, 68  Selected 
pharmacokinetic parameters from these studies are presented in Table 7.  El-Aty et al.68 
reported the pharmacokinetics of florfenicol in rabbits following IV, IM, and PO doses of 
30 mg/kg.  Following IV administration, florfenicol was rapidly eliminated and could 
only be detected up to 10 hours after administration.  Interestingly, this study described 
absorption rate-dependent elimination, also known as “flip-flop” kinetics, following IM 
and PO administration.  Park et al.67 described the pharmacokinetics of florfenicol and its 
major metabolite, florfenicol amine, in rabbits following IV and PO administration of 20 
mg/kg. 
 McKellar et al.71 described the pharmacokinetics of florfenicol in horses and 
ponies after IV, IM, and PO doses 22 of mg/kg.  The pharmacokinetic data from this 
study are presented in Table 8.  These authors reported that florfenicol was well absorbed 
following both IM and PO dosing with the PO dose resulting in higher, but shorter lived, 
concentrations compared to IM dosing.  All of the horses in this study developed loose 
stool following florfenicol administration causing the authors to discourage use of 
florfenicol in horses until further safety studies could be conducted. 
 The pharmacokinetics of florfenicol have been described in a number of aquatic 
species under a variety of circumstances.  Species studied include atlantic salmon,72,73 
 9
korean catfish,74 cod,75 koi carp and threespot gourami,76 red pacu,77 and white-spotted 
bamboo sharks.78  Selected pharmacokinetic parameters from these studies are presented 
in Table 9.   Florfenicol depletion studies have been conducted in atlantic salmon73 and 
channel catfish85 for the purposes of establishing appropriate withdrawal periods.  
Stamper et al.69 described the pharmacokinetics of florfenicol in loggerhead sea turtles.  
This study had a very small number of experimental units and data from this study are not 
presented.   
 Cook et al.70 described the pharmacokinetics of florfenicol in rhesus macaques 
following an IM dose of 50 mg/kg.  The data from this study was presented as individual 
animal data, and means, standard deviations, and standard errors were not provided.  
Median values were presented in the text.  Data from this study are not presented.  These 
authors concluded that administration of florfenicol to rhesus macaques at a dose of 
50mg/kg IM every 48 hours should be an effective treatment for common infectious 
conditions. 
  Several investigators have described the pharmacokinetics of florfenicol in cattle.  
The pharmacokinetic parameters reported in these studies are presented in Table 10.  In 
1986, Varma et al.50 described the pharmacokinetics of florfenicol in veal calves 
following a dose of 22 mg/kg administered IV, PO to fed calves, and PO to fasted calves.   
Calves that had been fasted for 12 hours prior to drug administration had higher serum 
concentrations, shorter time to Cmax, and higher bioavailability than calves that had been 
fed immediately prior to drug administration.  Adams et al.49 reported the 
pharmacokinetics of florfenicol after IV administration of 11 mg/kg in veal calves.  This 
study also reported the pharmacokinetics and tissue concentrations of florfenicol 
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following oral doses of 11 mg/kg every twelve hours for seven doses.49  The IV study 
demonstrated rapid distribution and elimination of florfenicol while the multiple dose PO 
study found a prolonged absorption phase in two calves that resulted in these calves 
exhibiting “flip-flop” kinetics.  Florfenicol was found in the highest concentrations in the 
urine, kidney, and bile.  Bretzlaff et al.47 described the pharmacokinetics of florfenicol in 
non-lactating dairy cattle following an IV dose of 50 mg/kg.  These authors also 
evaluated the effect of florfenicol on phagocytosis by blood neutrophils and found that, at 
all concentrations tested, florfenicol inhibited phagocytosis by neutrophils.  They stated 
that the clinical significance of this finding was unknown.    Soback et al.48 described the 
pharmacokinetics of florfenicol following IV, IM and intra-mammary (IMM) doses of 20 
mg/kg in lactating cows.  Interestingly, florfenicol was more rapidly absorbed and 
reached higher serum concentrations following IMM dosing compared to IM dosing.  
These authors also describe absorption rate-dependent, or “flip-flop” kinetics following 
IM administration indicating that the drug is absorbed slowly from the IM administration 
site.  Following IV and IM administration of 20 mg/kg florfenicol to feeder calves, Lobell 
et al.84 reported a median bioavailability of 78.5%.  The plasma and cerebrospinal fluid 
(CSF) pharmacokinetics of florfenicol following an IV dose of 20 mg/kg have been 
described by de Craene et al.46  These authors reported a maximum CSF concentration of 
4.67 μg/ml achieved 2 hours after dosing, indicating that florfenicol effectively crossed 
the blood-brain barrier.  Varma et al.86 described the pharmacokinetics of florfenicol 
following a SQ dose of 40 mg/kg and two IM doses of 20 mg/kg administered 48 hours 
apart.  Florfenicol was absorbed rapidly after SQ administration and the single SQ dose 
resulted in an AUC value similar to that obtained after the two IM doses. 
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Tourniquet Use 
 Tourniquet use is common in human surgery to reduce blood loss and provide a 
bloodless surgical field.87  The application of regional anesthesia distal to a tourniquet is 
also practiced.88  In veterinary medicine, tourniquets are used for similar purposes.  
Tourniquets are routinely applied in the application of intravenous regional anesthesia89,90 
and regional antibiotic delivery91,92 in a variety of species including horses,93 cattle,91,94 
sheep,95 dogs,96 and cats.97  Tourniquet use in veterinary surgery has been reviewed.98 
 Application of a tourniquet to a limb interrupts blood flow and induces ischemia 
distal to the tourniquet.99  The physiologic effects of tourniquet application to the limb 
have been investigated in cattle100,101 and horses.102,103  Singh et al.100 studied the effects 
of a tourniquet applied proximal to the elbow and left in place for 90 minutes in buffalo 
calves.  They found that the tourniquet induced a significant decrease in pH and an 
increase in carbon dioxide concentration in the limb distal to the tourniquet.  They state 
that the pH returned to baseline values 5 minutes after tourniquet release but then 
increased above baseline values and remained elevated throughout the study period (150 
minutes).  These authors also state that oxygen exchange in the limb tissue was impaired 
throughout the study period.  These findings led them to conclude that tourniquet 
application for periods of 90 minutes was not safe in buffalo calves.  In a similar study 
involving cattle, Chawla et al.101 investigated the effects of a tourniquet placed proximal 
to the elbow and left in place for 60 minutes.  The findings of this study were similar to 
those of Singh et al.100 leading the authors to conclude that tourniquet application in 
buffaloes for 60 minutes is unsafe.  Scott et al.102 investigated the effects of a tourniquet 
applied to the distal limb of horses for 120 minutes.  Tourniquet application resulted in a 
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decrease in pH, an increase in potassium concentrations, and a decrease in hematocrit in 
the tourniqueted limb.  Interestingly, these values all returned to normal within 15 
minutes after tourniquet removal.  Sandler et al.103 evaluated the vascular responses of the 
equine thoracic limb following tourniquet application.  These authors demonstrated 
reactive hyperemia following tourniquet release and found that both blood flow and 
blood pressure returned to normal within 10 minutes of tourniquet removal.  The findings 
of Chawla et al.101 and Singh et al.100 are interesting when compared to the findings of 
Scott et al.102 and Sandler et al.103 and in the light of the common clinical use of 
tourniquets in bovine practice.  Several authors have described regional intravenous 
anesthesia89,90,94,104-111 and regional antibiotic perfusion91,112 in cattle.  All of these studies 
involve the use of some sort of tourniquet and none of them report adverse reactions to 
the tourniquet. 
 Although tourniquet use is common, it is not without risks.  Reported 
complications in humans include pain associated with tourniquet application,113,114 deep 
venous thrombosis,115,116 vasospasm,117 nerve injury,118,119 and pulmonary embolism.120-
122  Tourniquet application has also been shown to result in increased systemic blood 
pressure.123-125  
 There is controversy in the literature concerning the affect of tourniquet 
application on the development of deep venous thrombosis (DVT).  While some studies 
have concluded that tourniquet use increases the development of DVT,115,116 others have 
found no correlation between tourniquet use and the risk of DVT.126,127  Deep venous 
thrombosis has been reported in cattle following regional antibiotic delivery.128,129  
Steiner et al.128 reported venous thrombosis in two out of fifteen cows following 
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intravenous regional administration of benzyl penicillin.  The authors of this report 
attributed the complications to the high doses of penicillin rather than to the use of the 
tourniquet.  Kofler et al.129 reported venous thrombosis in two cows but only one of these 
cows had undergone regional perfusion.   
 Persistent lameness has been reported following regional intravenous anesthesia 
of the forelimb of buffalo calves.111  In this study, the tourniquet was placed proximal to 
the elbow and left in place for over one hour.  All of the animals eventually recovered. 
 The tourniquet pressure and the length of time the tourniquet is applied are 
thought to be the most important contributing factors in the development of 
complications to tourniquet use.  A variety of pressure and application times have been 
reported in both the human and veterinary literature.  Reported tourniquet pressures in 
humans and veterinary patients range from 250-800 mmHg.  Several authors recommend 
a maximum pressure of 100 mmHg greater than systolic blood pressure88,130.  Controlled 
tourniquet pressure is difficult to achieve in large animal clinical practice because 
pneumatic tourniquets are rarely used in these settings.  Several authors89,90,94,104-106 have 
performed regional intravenous anesthesia to the distal limb of cattle using rubber 
tourniquets without any control of tourniquet pressure.  None of these authors report 
adverse reactions to the tourniquet use. 
 Three hours has been reported to be the maximum safe duration of tourniquet 
ischemia in human surgery.131,132  The application of a tourniquet above the elbow of 
cattle for 90 minutes100 and 60 minutes101 have been described as unsafe.  For the purpose 
of regional antibiotic or anesthetic delivery, tourniquet times in current veterinary 
practice rarely exceed one hour.  Also, in current large animal practice, the tourniquet is 
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typically applied to the proximal or mid-metatarsal region where there is much less risk 
of muscle damage.   
  
Regional Limb Perfusion in Large Animal Veterinary Medicine 
 Regional limb perfusion may be performed via intravenous (RIVP) or 
intraosseous (RIOP) routes.  Regional limb perfusion with antimicrobial agents was 
reported in humans in the late 1950’s and early 1960’s for the treatment of chronic 
osteomyelitis.133  Regional intravenous perfusion is easily performed on the distal limb 
by placing a tourniquet on the limb and infusing the antibiotic distal to the tourniquet.  
Higher on the limb, the affected area may be isolated by placing a tourniquet proximal 
and distal to the area to be infused.  It is thought that increased intravascular pressure 
resulting from the tourniquet distends venules and allows the antibiotic to gain access to 
the capillaries through back diffusion into bone and soft tissues.  The antibiotic may be 
infused into any accessible vein in the target area with the dorsal common digital vein 
being the most easily accessible and commonly used vein in the distal limb of cattle.    
 This technique has been well described in the equine literature92,134-137 and a 
recent review93 of regional limb perfusion in horses has been published.  The 
pharmacokinetics of cefazolin112 and ceftiofur91 after RIVP in cattle have been defined.  
Both of these studies demonstrated antibiotic concentrations above therapeutic levels for 
commonly encountered pathogens.  Additionally, no adverse effects of RIVP were 
observed.  Even though these studies demonstrate that cefazolin and ceftiofur should be 
effective in treating orthopedic infections, both studies were pharmacokinetic studies 
utilizing normal animals.  Clinical reports of this technique in cattle are rare; however, 
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the equine literature contains several successful reports of the use of regional limb 
perfusion (RLP) for the treatment of orthopedic infections.  Recently, the synovial fluid 
pharmacokinetics of ceftiofur after RIVP in the horse have been described.137    
 Aminoglycosides are a common choice for RLP in horses.138    In one study,41 
experimentally infected antebrachiocarpal joints were treated with RIVP of gentamicin 
sulfate or systemic intravenous gentamicin injection.  Regional intravenous perfusion 
resulted in significantly higher gentamicin concentrations in synovial fluid compared to 
systemic administration.  Also, culture of synovial fluid and synovial membrane was 
negative for two out of three horses undergoing RIVP while bacteria were isolated from 
all three horses undergoing systemic administration of gentamicin.  Another study134 
reported the successful treatment of osteomyelitis associated with surgical implants using 
amikacin administered via RIVP. 
 Complications associated with RIVP are uncommon.  In one report,128 two out 
fifteen cows undergoing RIVP of the distal limb suffered severe thrombosis of all vessels 
distal to the tourniquet.  The thrombosis was attributed to extremely high concentrations 
of benzylpenicillin.  Another report129 describes two cows with thrombosis of distal limb 
veins but only one of these cows had received RIVP.   
 Regional limb perfusion may also be performed via an intraosseous route.  This 
technique is useful when intravenous access is difficult to achieve or maintain.139  The 
technique is relatively easy to perform and involves either the insertion of a catheter into 
a hole drilled into the medullary cavity139-142 or the insertion of a cannulated bone screw 
with a catheter adapter.134,135,143  
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 Regional intravenous perfusion and RIOP have been compared.141,143  In both 
studies, both RIVP and RIOP resulted in concentrations of amikacin well above 
recommended therapeutic levels.  However, RIVP resulted in higher concentrations in 
synovial fluid when compared to RIOP.  The pharmacokinetics of vancomycin after both 
RIVP and RIOP in the horse have been recently described;144,145 however, this antibiotic 
cannot be used in food animals and will not be discussed further.  Regional intraosseus 
perfusion has been shown to be effective in treating clinical cases,134,140 and can be 
performed without general anesthesia.142  There are no known published reports of the 
use of RIOP in the treatment of clinical cases in food animals; however, the technique has 
been used experimentally in pigs.146-148   
 
 
 
 
 
 
 
 
CHAPTER III 
 
 
METHODOLOGY 
 
Animal Selection 
 This study utilized six adult mixed breed beef cows ranging from 6-10 years of 
age and 445 kg to 688 kg body weight.   Two cows exhibited minor Bos indicus breed 
characteristics.  The cows were identified with individual ear tags labeled with single 
letters.  No clinical signs of lameness were evident at the beginning of the study.  
Throughout the study, the cows were housed in stalls in the Veterinary Teaching Hospital 
and provided free choice grass hay and water. 
Catheter Placement 
 The cows were sedated with 25 mg xylazinef IV and restrained in lateral 
recumbency in a hydraulic tilt chute (Figure 2).  The distal aspect of the left rear limb, 
beginning at the mid-metatarsus, was clipped and cleaned with chlorhexidine scrub.  A 
rubber tourniquet was placed tightly around the mid-metatarsus.  Anesthesia of the distal 
limb was accomplished using a ring block around the mid-metatarsus with 2% lidocaineg 
just distal to the tourniquet.  The claws were covered with a sterile glove and the skin 
over the distal limb was prepared in sterile fashion. 
                                                 
f Xylazine 20 Injection, 20 mg/ml, The Butler Company, Dublin, OH 
g Lidocaine 2% Injectable Solution, The Butler Company, Dublin, OH 
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Figure 2.  Photograph of a cow restrained on a hydraulic tilt table in preparation for 
catheter placement. 
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 Venipuncture of the dorsal common digital vein was performed using an 18 gauge 
2.5 cm needle.  A sterile guide wire was placed through the needle into the vein and the 
needle was removed.  A stab incision was then made over the vein with a #15 scalpel 
blade using the wire as a guide.  An 18 gauge, 4.8 cm catheterh was then fed over the 
wire  
and into the vein.  The wire was then removed and a T-porti with injection capj was then
placed on the catheter.  The catheter and T-port were sutured into place using 2-0 nylon 
 
).   
d 
de 
 an 
rees 
 the 
                                                
suture.  The same procedure was repeated for the plantar vein of the lateral digit (PVLD
 The metatarsophalangeal joint was then catheterized using a 20 gauge epidural 
infusion catheterk.  Arthrocentesis was performed over the craniolateral aspect of the 
joint using an 18 gauge 3.8 cm needle.  An injection cap was placed on the needle an
30-50 mls of sterile saline was infused into the joint through a 19 gauge butterfly 
catheterl placed in the injection cap.  As the joint was distended, the caudolateral aspect 
of the joint was palpated to identify the joint pouch.  A 0.5 cm stab incision was ma
over the joint pouch with a # 15 blade and a 19 gauge 9 cm Touhy needle was placed in 
the caudolateral joint pouch.  This needle was placed in the stab incision and held at
angle of approximately 30 degrees lateral to the median plane of the limb and 15 deg
caudal to the dorsal plane of the limb.  The needle was advanced until it entered
 
h 1.3 x 48 mm Intravenous Catheter, BD Insyte, Franklin Lakes, NJ 
i Non-DEHP T Connector, Medex, Dublin, OH 
j Prepierced Reseal Male Adapter Plug-Short, Hospira©, Forest Lake, IL 
k Periflex® Continuous Epidural Anesthesia Set, B. Braun Medical, Bethlehem, PA 
l Surflo® Winged Infusion Set, 19 gauge 0.75 inch thin walled needle with 12 inch tubing, Terumo© 
Medical, Somerset, NJ 
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distended joint.  A curved 16 gauge 10 cm needle was placed through the skin 
approximately 4 cm proximal to the stab incision, advanced under the skin, and exited 
through the stab incision.  This needle was used to create a subcutaneous tunnel through 
which the catheter tubing could be placed.  The catheter tubing was passed approximately
1.5 cm into the joint through the Touhy needle.  The Touhy needle was removed and
catheter tubing was shortened to the desired length.  The free end of the tubing was 
passed through the 16 gauge needle and the needle was removed.  The tubing was pulled
through the subcutaneous tunnel until it was no longer exposed at the stab incision.  An 
injection cap was placed on the catheter tubing and the catheter was secured to
using 2-0 Nylon in a Chinese finger cuff pattern.  Figure 3 shows a foot fully 
instrumented with catheters in the dorsal common digital vein, the plantar vein of the
lateral digit and the metatarsophalangeal joint. A light bandage was placed over the 
catheters for protection.  Sedation was reversed when needed using tolazoline
 
 the 
 
 the skin 
 
rs were placed at least 24 hours prior to beginning the study.   
m at 1 
mg/kg IV.  All cathete
Dosage Calculation 
 Selecting the appropriate dose is one of the uncertainties associated with the use 
of RIVP.  The dose of 2.2 mg/kg (1mg/lb) used in this study was determined by wei
the distal limb (distal to mid-metatarsus) of one cow and calculating a dose for this 
weight using a dose of 40mg/kg.  The dose of 2.2 mg/kg of whole body weight was 
chosen because it provided between 2 and 3 times the high end of the label dose (40 
mg/kg) for the weight of the distal limb.  At this dose, the volume of florfen
ghing 
icol delivered 
as small (ranging from 3.3 to 5.0 ml) and could be readily administered. 
                                                
w
 
m Tolazoline Injectable Solution, 100 mg/ml, Lloyd Laboratories, Shenandoah, IA 
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Figure 3.  Photograph of bovine foot showing placement of catheters in the dorsal 
common digital vein (small arrow), the plantar vein of the lateral digit (large, open 
rrow), and the metatarsophalangeal joint (large, closed arrow). a
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 Drug Administration and Sample Collection 
 Each cow was sedated with 25 mg xylazine IV and restrained in lateral 
recumbency in the hydraulic tilt chute.  A pneumatic tourniquetn was placed around the 
limb at the mid-metatarsus.  Prior to each sample collection, 3 ml of blood and 0.2 m
synovial fluid were collected and discarded.  The synovial catheter had a volume of 
approximately 0.1 ml.  A 3 ml sample of blood was collected from the plantar vein of the 
lateral digit and both IV catheters were flushed with 3 ml of heparinized saline.  A 0.
sample of synovial fluid was collected from the metatarsophalangeal joint catheter.  
These first samples served as the time 0 samples.  The tourniquet was inflated to 300 
mmHg.  Florfenicol
l of 
5 ml 
 
l of 
 
 the 
 8, 
                                                
o was administered at 2.2 mg/kg body weight into the dorsal common
digital vein (time 0).  The catheter was not flushed after florfenicol administration.  The 
volume of the catheter and T-port was determined to be 0.6 ml so an additional 0.6 m
florfenicol was added to the dose to account for the volume of the catheter since the 
catheter was not flushed.  A 3 ml blood sample and a synovial fluid sample ranging from
0.3- 0.5 ml were collected as described above at 15, 30 and 45 minutes post florfenicol 
administration.  Systemic blood samples were collected at the same time points from
left jugular vein via venipuncture.  The tourniquet was removed after the 45 minute 
sample and the cow was allowed to stand.  Sample collection continued at 1, 1.5, 2, 4,
12, 18, and 24 hours after florfenicol administration.  After the 45 minute sample, all 
remaining samples were collected with the cows standing in a chute.  Blood samples 
 
n Portable Tourniquet System, Delfi Medical Innovations Inc., Vancouver, BC, Canada 
o Florfenicol Injectable Solution, 300 mg/ml, Schering Plough Animal Health, Omaha, NE  
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were collected in plain glass tubes and synovial fluid samples were placed in 0.5 ml pla
plastic cryotubes
in 
ly 
 
r 
table 
amples subjected to three freeze-thaw cycles at -20˚ C over a 2 month 
p. Synovial fluid samples were labeled and placed on ice immediate
after collection.  Blood samples allowed to clot at room temperature and serum was
harvested by centrifugation.  Serum was placed in 1.5 ml plain plastic cryotubesq.  
Samples that could not be centrifuged within 2 hours of collection were refrigerated and 
all serum was harvested within 18 hours of collection.  Florfenicol recovery rates greate
than 99% have been demonstrated in plasma and cerebrospinal fluid samples stored at 
room temperature for 24 hours.46  Synovial fluid samples that were contaminated with 
blood were centrifuged, and the supernatant was collected.91,112  Synovial fluid samples 
with significant blood contamination were from cow A only.  Serum and synovial fluid 
samples were frozen at -20˚ C until analysis could be performed.46  Florfenicol is s
in plasma s
period.149  
Sample Analysis 
 The serum and synovial joint fluid samples were assayed for florfenicol usi
reverse-phase high pressure liquid chromatography (HPLC) with ultraviolet (UV) 
detection.  The laboratory used other published references as a guide
ng 
ected 
r s t a extraction was accomplished 
                                                
48,49,83,84, but added 
some modifications to the procedure to produce an assay adapted for the fluids coll
from cattle in this study.    The HPLC system consisted of a quaternary pump and 
degasser , automated sampler , and UV detector .  Plasm
 
ngton, DE 
p Microcentrifuge tube, 0.5 ml, SCI Dynamics, Adelphia, NJ 
q Microcentrifuge tubes, 1.5 ml, SCI Dynamics, Adelphia, NJ 
r Agilent 1000 series solvent delivery system.. Agilent Technologies Wilmi
s Agilent 1000 series autosampler. Agilent Technologies Wilmington, DE 
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with solid phase hydrophilic-lipophilic balanced (HLB) extraction cartridgesu, 
conditioned with 1 mL methanol, followed by 1 mL distilled water.  After the addition of 
200 µL of serum sample to the cartridge, it was washed with 1.0 mL distilled 
water:methanol (95:5).  The eluent was discarded.  The final elution was achieved with 
the addition of 1.0 mL methanol into a clean glass tube.  The eluate was evaporated in a 
hot water bath (45°C) under nitrogen for 20-25 minutes and reconstituted with 200 μL of 
mobile phase.  
  A reverse phase stable bond 4.6 mm x 15 cm C-8 columnv, heated to 40°C, 
achieved separation.  The mobile phase consisted of 70% water and 30% acetonitrile.  
The UV detector was set to a wavelength of 223 nm. The volume for each injection was 
20 μL.  Retention time for florfenicol was 4.5-5.0 minutes.  Chromatograms were 
integrated with computer software.w   
 A stock solution of florfenicol was prepared by dissolving a pure analytical 
reference standard of florfenicolx in acetonitrile at a concentration of 1 mg/mL and stored 
in the refrigerator.  The analytical reference standard solution was used to make 
calibration standards and to fortify quality control (QC) samples.    The 1 mg/mL stock 
solution was further diluted serially with distilled water to concentrations ranging from 
1000 µg/mL to 3.91 µg/mL.  Standard curves for plasma analysis were prepared by 
fortifying 200 µL of pooled bovine serum with 20 µL of the diluted stock solutions to 
                                                                                                                                                 
t Agilent 1000 series variable wavelength detector (VWD). Agilent Technologies Wilmington, DE 
u Oasis HLB solid phase extraction cartridges.  Waters Corporation, USA.   
v Zorbax Eclipse XDB-C8 4.6 mm x 15 cm column. Agilent Technologies Wilmington, DE. 
w Agilent 1100 series Chemstation software, Agilent Technologies, Wilmington, DE. 
x Florfenicol reference standard donated by Schering Plough Corporation.   
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make eleven calibration standards (including zero) of florfenicol in plasma ranging from
100 µg/mL to 0.195 µg/mL.  Unfortified cattle serum was used as a blank and to verif
that the assay contained no interfering compounds.  The fortified calibration samples 
were processed and prepared exactly as described for the incurred samples.  For each 
day’s run, a fresh set of calibration and blank samples were prepared.  Calibration curves 
of peak height versus concentration were calculated by use of linear-regression
All calibration curves were linear with a R
 
y 
 analysis. 
.  The laboratory used guidelines published by the United States Pharmacopeia 
 
s 
ere then 
ss 
re calibration samples.  The calibration range was the same as for the 
rum samples. 
2 value of 0.99 or higher.  Limit of 
quantification for florfenicol in cattle serum was 0.195 µg/mL, which was determined 
from the lowest point on a linear calibration curve that produced an appropriate signal-to-
noise ratio
(2006).   
 The synovial fluid samples were prepared in the same manner as that of the serum
samples, except for slight modification.  Because synovial fluid is viscous, processing i
difficult in extraction cartridges.  Therefore, hyaluronidase (10 µL) was added to each 
sample prior to processing followed by vortexing.  The synovial fluid samples w
processed in the same manner as the serum.  For the calibration samples, blank 
(untreated) synovial fluid was collected from cattle with no evidence of lameness or gro
musculoskeletal pathology that were presented to the college’s necropsy service.  This 
synovial fluid was fortified (spiked) with florfenicol in the same manner as the serum 
samples to prepa
se
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 Pharmacokinetic Analysis  
Serum and joint fluid concentrations of florfenicol after the injection into the 
digital vein were analyzed using a computer programy.  A non-compartmental analy
(NCA) that does not assume any compartmental structure was used for the ana
because this was not a standard intravenous bolus injection and calculation of 
compartmental parameters wou
sis 
lysis 
ld have been subject to error.  Calculation methods were 
om p
 
.  
of 
s extrapolated using the trapezoidal rule was calculated by use of 
e foll
 
or synovial fluid samples because this was a regional administration of the drug, and 
                                                
fr ublished methods.150,151 
 For the NCA, the AUC from time 0 to the last measured concentration, defined by
the limit of quantization (LOQ), was calculated using the log-linear trapezoidal method
The AUC from time 0 to infinity was calculated by adding the terminal portion of the 
curve, estimated from the relationship Ct/ λZ, to the AUC0-Ct, where λZ is the terminal 
rate constant of the curve, and Ct is the last measured concentration point.  The percent 
the AUCinfinity that wa
th owing equation:  
 % AUC Extrapolated = (AUCinfinity – AUC0 to Ct)/AUCinfinity  x 100. 
Values for the maximum concentration after dosing (CMAX) and time to maximum 
plasma concentration (TMAX) were taken directly from the data.  Half-lives were 
calculated from the terminal slope:  T½ = ln 2.0/(terminal rate constant), where ln 2.0 is
the natural logarithm of 2.0.  Traditional pharmacokinetic parameters such as apparent 
volume of distribution and systemic clearance (CL) were not calculated for digital serum 
 
y WinNonLin. Version 5.0.1 Pharsight Corporation, Mountain View California.   
 37
 38
 and 
ailability. 
these are whole-body parameters.  For the jugular serum samples, clearance (Cl/F)
volume of distribution at steady state (VDSS/F) were adjusted for bioav
Statistical Analysis 
 Data were analyzed using PC SAS Version 9.2z.  The experimental design was a 
randomized complete block design with repeated measures.  The cow was considered the 
blocking variable, and location the main unit factor.  Time was the repeated measures 
factor.  Because of normality and heterogeneity of variance problems associated with the 
response variable, a natural log(x+1) transformation was used to stabilize and normalize 
the data.  PROC MIXED in SAS was used to conduct the analysis of variance, and an  
autoregressive period 1 covariance structure used to model the intra-location covariances 
across time.  An LSMEANS statement with a SLICE option was also used to evaluate the 
simple effects of time given location and location given time.  If the test of simple effects 
was significant, pairwise t tests using the DIFF option was used to separate the means.   
                                                 
z SAS Institute, Cary, NC 
CHAPTER IV 
 
 
FINDINGS 
Florfenicol Concentrations and Pharmacokinetics  
 No lameness or other adverse effects were observed throughout the study period.  
Samples could not be collected from the digital vein for cow D after the 4 hour sample or 
cow K at the 18 hour sample due to loss of the catheter.  The 24 hour sample for cow K 
was collected via venipuncture of the PVLD.  Also, synovial fluid samples were not 
collected from cow A at the 0.75 and 1 hour sampling times due to difficulties with the 
catheter.  
 The concentration versus time profiles of florfenicol for the digital blood (DIG), 
synovial fluid (SYN), and systemic blood (JUG) are shown in Figures 4-6 respectively.  
The mean peak concentrations for the DIG, SYN, and JUG samples were 714.8 ± 301.9, 
39.2 ± 29.4, and 5.9 ± 1.4 μg/ml, respectively.  At 0.25 hours post infusion (HPI), 
florfenicol concentration in DIG samples was significantly higher than either SYN or 
JUG samples.  At 0.5 and 0.75 HPI, concentrations at all sampling locations were 
significantly different.  After 8 HPI, no significant differences existed between sampling 
locations.  The mean florfenicol concentrations for each sampling location analyzed by 
sampling time are presented in Table 11.  Table 12 shows the mean florfenicol 
concentrations for each sampling location analyzed by sampling location.  For the DIG 
samples, the florfenicol concentration was significantly different at each time point up to 
the 8 hour sample.  For the SYN samples, a significant increase in florfenicol 
concentration was observed at the 0.5 hour time point and by 4 hours the concentration 
decreased to a level equal to the initial sample at 0.25 hours.  Significant decreases were 
 39
seen at 4, 8 and 12 hours, after which, significant differences were not observed.  For the 
JUG samples, a significant decrease in florfenicol concentration was seen at 8 hours.  
Further significant differences were not observed.   
 The mean pharmacokinetic parameters of florfenicol for DIG, SYN, and JUG 
samples are presented in Table 13.  Individual animal pharmacokinetic parameters for 
DIG, SYN, and JUG samples are presented in Tables 14-16, respectively.  The individual 
animal data are included because of obvious differences among the individuals.  Two of 
the animals, cow A and cow F, had lower drug concentrations in the digital vein.  The 
same animals had lower concentrations in the joint fluid.   
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Figure 4.  Mean ± SE florfenicol concentration vs. time for digital serum samples 
following intravenous regional perfusion of 2.2 mg/kg florfenicol. 
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Mean SYN Florfenicol Concentration vs. 
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Figure 5.  Mean ± SE florfenicol concentration vs. time for synovial fluid samples 
following intravenous regional perfusion of 2.2 mg/kg florfenicol. 
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Mean JUG Florfenicol Concentration vs. 
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Figure 6.  Mean ± SE florfenicol concentration vs. time for jugular serum samples 
following intravenous regional perfusion of 2.2 mg/kg florfenicol. 
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 Regional intravenous administration of florfenicol into the dorsal common digital 
vein produced very high drug concentrations in the digital serum.  These concentrations 
remained high until the tourniquet was removed, at which time the concentration 
decreased rapidly.  Even though the concentration of florfenicol decreased after 
tourniquet removal, the concentration remained above 1 μg/ml for 12 hours.  The 
pharmacokinetics of florfenicol after systemic intravenous administration have been 
reported.  An initial concentration of 65.68 μg/ml was reported following administration 
of 22 mg/kg body weight to veal calves.50  Another study reported an initial concentration 
of 39.7 μg/ml following administration of 20 mg/kg to feeder calves.84  The initial mean 
DIG concentration of 706.15 μg/ml following a much smaller total dose of florfenicol in 
this study demonstrates the effectiveness of RIVP in achieving high local drug 
concentrations.  The mean DIG florfenicol concentration at 24 hours was numerically 
greater than the concentration at 18 hours however; the difference was not statistically 
significant. 
 Administration of florfenicol via RIVP in this study produced high concentrations 
of florfenicol in the metatarsophalangeal joint.  The mean peak SYN concentration was 
39.19 μg/ml, and time to maximum concentration was 0.88 hours.  This peak 
concentration occurred after removal of the tourniquet indicating that absorption of 
florfenicol into the joint continued to occur after tourniquet removal in several cows.  
Florfenicol concentration remained above 1 μg/ml for 12 hours and was 0.25 μg/ml at 24 
hours.  Synovial fluid concentrations of florfenicol have not been previously reported. 
 The concentrations of florfenicol detected in the JUG samples remained low 
throughout the study.  Florfenicol concentrations in JUG samples slowly decreased until 
 50
 51
tourniquet removal, after which time there was a slight increase followed by a gradual 
decrease in florfenicol concentration.   
 
Elimination half-life and withdrawal information  
 The elimination half life for florfenicol observed in this study was slightly longer 
than other reports in the literature.  Reported elimination half-lives for florfenicol 
following intravenous administration to cattle include 2.87,50 3.0,48 and 2.6584 hours.  In 
this study, the mean half lives of florfenicol in DIG, SYN, and JUG samples were 4.09, 
3.81, and 4.77 hours, respectively.  Following intramuscular administration, the 
elimination half life of florfenicol ranges from 12.548 to 18.384 hours.  Following 
intramuscular administration at a dose of 20 mg/kg, florfenicol has a meat withdrawal 
time of 28 days.  Based on these data, administration of florfenicol via RIVP should not 
result in a prolonged withdrawal period compared to the current label recommendations. 
 
 
 
 
 
 
 
 
 
 CHAPTER V 
 
 
CONCLUSION 
Clinical Application    
  The data produced by this study indicated that RIVP administration of 
florfenicol should be a useful tool in the treatment of deep digital sepsis in cattle.  Most 
digital infections in cattle involve a mixed bacterial population including 
Arcanobacterium pyogenes and Fusobacterium necrophorum.38,152  A study153 involving 
445 cattle with appendicular skeletal infections found that A. pyogenes was the most 
common bacterial isolate.  Florfenicol is effective against both of these organisms.  The 
New Animal Drug Application for florfenicol (NADA-141-063) reports an MIC90 for F. 
necrophorum of 0.25 μg/ml.  A study of 49 A. pyogenes isolates from cattle and pigs 
reported an MIC90 of 1.56 μg/ml.154  A study of 16 A. pyogenes isolates from white-tailed 
deer reported an MIC90 of 0.5 μg/ml.155  The florfenicol concentrations from the DIG 
samples remained above the MIC90 for A. pyogenes for a minimum of 8 hours and above 
that for F. necrophorum for a minimum of 18 hours.  For the SYN samples, the 
concentration remained above the MIC90 for A. pyogenes for a minimum of 8 hours and 
above that for F. necrophorum for the full 24 hour sampling period.  
 Mycoplasma bovis is a common cause of infectious arthritis in calves, especially 
following an episode of respiratory disease.156  Minimum Inhibitory Concentrations and 
Minimum Mycoplasmacidal Concentrations (MMC) of florfenicol against M. bovis have 
been reported.157  That study reported an MIC90 of 16 μg/ml, an MMC50 of 16 μg/ml, and 
an MMC90 of 32 μg/ml.  Only danofloxacin was more effective than florfenicol.  
Regional intravenous perfusion of florfenicol produced synovial concentrations that 
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 exceeded both the MMC50 and the MMC90 for M. bovis.  Mycoplasmal arthritis typically 
occurs in the larger joints such as the carpus, elbow and stifle.   Regional perfusion can 
easily be performed for the carpal or tarsal joints but is difficult to perform on the larger, 
more proximal joints. 
 In order to be ideally suited for use in RIVP, an antibiotic should have 
bactericidal, concentration dependent activity.  Florfenicol is typically described as a 
time-dependent, bacteriostatic antibiotic.  However, recent research has demonstrated 
concentration dependent, bactericidal activity for florfenicol.45  Unfortunately, the 
organisms included in this study were respiratory tract pathogens and did not include F. 
necrophorum or A. pyogenes.  At this time, it is unknown if florfenicol possesses 
concentration dependent activity against these organisms.  Even if the activity of 
florfenicol is time-dependent against these target organisms, this study demonstrates that 
RIVP administration of florfenicol could be useful in the treatment of digital infections in 
cattle.  Florfenicol concentrations remained above the MIC90 of A. pyogenes for 8 hours 
in both the DIG and SYN samples and above the MIC90 of F. necrophorum for at least 18 
hours in the DIG samples and for 24 hours in the SYN samples. 
 Regional perfusion of florfenicol is best performed via venipuncture rather than 
through an indwelling intravenous catheter.  Due to the poor solubility of florfenicol in 
water (less than 2 mg/mlaa), flushing a catheter with heparinized saline or other aqueous 
solution following florfenicol administration will result in precipitation of the florfenicol 
and obstruction of the catheter.   Dilution of florfenicol with sterile water combined with 
                                                 
aa http://www.fda.gov/cvm/FOI/141-063EA.pdf 
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 a solubilizing agent, dimethyl formamide, has been described.67,68  This compound is a 
carcinogen158 and causes birth defects,159 therefore it cannot be used in food animals. 
Summary  
 In summary, RIVP of florfenicol at a dose of 2.2 mg/kg resulted in high drug 
concentrations in both the serum and synovial fluid of the distal limb while maintaining 
low systemic drug concentration.  Florfenicol demonstrates concentration dependent 
killing activity against some pathogens.45  The most likely pathogens encountered in 
cases of deep digital sepsis include Fusobacterium necrophorum and Arcanobacterium 
pyogenes.38    The concentrations of florfenicol achieved in the distal limb in this study 
greatly exceeded the published MIC of these pathogens.  In addition, the concentration of 
florfenicol in synovial fluid remained above the MIC of F. necrophorum for up to 24 
hours.  These findings indicate that RIVP of florfenicol should be useful in the treatment 
of deep digital sepsis whether the activity of florfenicol against these pathogens is 
concentration dependent or time dependent. 
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Scope and Method of Study:  
 Six healthy adult cows were used in this study.  Intravenous catheters were placed 
in the dorsal common digital vein (DCDV) and the plantar vein of the lateral digit 
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Findings and Conclusions:   
 The pharmacokinetic parameters of florfenicol following regional intravenous 
perfusion (RIVP) are shown (table).    
   
 
 
 RIVP of florfenicol produced high concentrations in DIG and SYN samples while the 
concentration in JUG samples remained relatively low.  RIVP of florfenicol may be 
useful in the treatment of infectious processes involving the distal limb of cattle. 
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